BioSpace News Archive

miRagen Therapeutics, Inc. (NASDAQ: MGEN), today reported operating highlights and financial results for the quarter and full-year ended December 31, 2019 and provided an outlook for 2020.

Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Arctic Vision, a company focused on developing and commercializing innovative ophthalmology therapies in China and Asia, has acquired an exclusive license for the commercialization and development of XIPERE

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that the company will host a conference call and webcast on Monday, March 16, 2020 at 8:00 a.m. ET to report its fourth quarter 2019 financial results and other business highlights.

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell its ordinary shares

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced it will release its fourth quarter and full year 2019 financial results after the market closes on Wednesday, March 25, 2020.

Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a diversified medical aesthetics company, today announced its financial results for the fourth quarter and full year ended December 31, 2019.

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today reported financial results for the three months and full-year ended December 31, 2019, and provided an overview of recent corporate highlights.

Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that Dr. Lindsay Fourman, from Harvard Medical School, presented data demonstrating that visceral fat is a clinical predictor of liver fibrosis and liver fibrosis progression in an oral presentation during CROI 2020.

XtalPi Inc. (“XtalPi”), an algorithm-driven artificial intelligence (AI) pharmaceutical technology company, and Porton Pharma Solutions Ltd. (“Porton”), a contract development and manufacturing organization (CDMO), announces the signing of a strategic collaboration to integrate XtalPi’s next-generation computational tools with Porton’s experimental expertise to further empower pharmaceutical research in drug design and pre-clinical development.

Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, publishes its financial results for 2019 and provides an update on its product portfolio.